云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议

上海, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀(HKEX 1952.HK,以下简称"公司"),一家专注于创新药研发、临床开发、制造及商业化的生物制药公司,今日宣布与陕西麦科奥特医药科技股份有限公司(以下简称"麦科奥特")签署独家商业化许可协议,获得MT1013在中国及亚太区(日本除外)的独家商业化授权。MT1013为全球首创的双靶点受体激动剂多肽,可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体,开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应,强化产品布局,巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位,并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。根据协议,云顶新耀将向麦科奥特支付人民币2亿元首付款,以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。中国III期临床研究正在进行中,相关临床开发费用将由麦科奥特承担。MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药,2025年获美国肾脏病学会(ASN)年会"Late-Breaking"收录。其开创性地融合了"钙敏感受体(CaSR)+成骨生长肽(OGP)模拟"双重作用机制,解决了PTH、钙、磷代谢平衡的问题,这一全新设计使其在治疗继发性甲状旁腺功能亢进(SHPT)及相关骨代谢疾病时,首次创造性的从源头上控制病情,且能通过直接激活成骨通路,主动促进骨形成与修复,实现从"间接抑制骨吸收"到"主动促进骨生成"的治疗创新升级。临床研究证实,MT1013在慢性肾病接受维持性血液透析伴继发性甲状旁腺功能亢进患者中,起效迅速、效力强且持久,安全性良好,在综合达标率(iPTH, 血钙,血磷均达标)、血钙钙化指标的控制及心血管获益前景上均展示出超越现有疗法的潜力。目前,MT1013正在中国开展针对该患者群体的III期临床研究,已入组超50%。SHPT是慢性肾脏病(CKD)患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化,显著增加骨折、心血管事件和死亡风险,是影响CKD患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大,SHPT及其相关治疗需求亦不断增长。数据显示,全球CKD患者人数已由2019年的9.052亿人增至2024年的10.655亿人,预计2030年将超12亿人,2035年将超15亿人;同期全球SHPT患者人数亦持续增长,预计2030年将达约1.899亿人,2035年将达约2.217亿人,临床需求亟待满足。云顶新耀董事会主席吴以芳表示:"我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下,继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产,有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物,MT1013将与公司现有的肾科产品组合形成高度协同,进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上,正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措,标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来,双方将协同推进MT1013的开发与商业化,为更广泛的肾病患者提供创新治疗选择。"麦科奥特创始人、董事长王冰博士表示:"我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系,是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果,代表着公司在慢病创新治疗领域深耕的重要里程碑达成,其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作,加速该产品的临床开发和上市进程,共同满足广大未满足的临床需求,开启肾病领域治疗的全新篇章。"MT1013已完成关键II期临床研究,数据显示,MT1013在维持性血液透析伴SHPT患者中,展现出强效且持久的iPTH抑制能力,并在与依特卡肽头对头比较中实现了综合管理的优势——其iPTH、血钙、血磷三项同时达标率更高,降磷及降低心血管风险标志物FGF-23的优势更强,加之MT1013在长达52周的治疗中也为患者人群带来了显著的骨密度提升及骨代谢标志物改善,逐步验证了其独特的双重机制在SHPT患者中综合管理及改善骨骼健康方面的潜在临床获益。目前MT1013已进入以西那卡塞为阳性对照的确证性III期临床试验。该III期试验已在全国范围内启动超过100家研究中心,计划招募约424名患者,主要针对慢性肾脏病维持性血液透析伴 SHPT的患者群体。关于MT1013MT1013为全球首创的双靶点受体激动剂多肽,可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体,开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT),并计划拓展至包括慢性肾病性矿物质和骨代谢异常(CKD-MBD)伴骨质疏松及未接受透析的SHPT在内的额外适应症。MT1013已于2025年5月完成针对SHPT的II期临床研究(MT1013-II-C01),并已进入以西那卡塞为对照的III期临床研究。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司,致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地,并严格按照国家药品监督管理局(NMPA)和欧洲药品管理局(EMA)的 GMP 要求及世界卫生组织(WHO)PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM(心血管、肾脏及代谢)等疾病治疗领域,已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台,并以拥有全球权益的自研 mRNA 平台为基础,持续推进mRNA in vivo CAR-T 与 mRNA 肿瘤疫苗等现有管线,同时通过引进及生态孵化潜力平台,拓展研发能力,同时强化全球化布局,加快国际化发展进程。更多信息,请访问公司官网:www.everestmedicines.com。关于麦科奥特陕西麦科奥特医药科技股份有限公司(以下简称"麦科奥特")于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者,是多肽类药物研发的优秀平台之一,具有筛选多靶点多肽药物的特殊机制,具备开发First-in-class和Best-in-class品种的平台型研发能力,现已储备多个新药品种,其中进入临床研发的有7个原研创新药管线,包括1个临床三期阶段,3个临床二期阶段,3个临床一期阶段。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。更多信息,请访问公司官网:www.micot.cn。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述,乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期,可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证,会受到风险、不确定性及其他因素的影响,有些乃超出本公司的控制范围,难以预计。因此,受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响,实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务,除非法律要求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hitachi significantly expands exhibits at the “Hitachi Building Solutions Lab”, a research facility for collaborative creation with customers

- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on March 2, 2026. The exhibition is being expanded to accelerate digital innovation in the field of buildings, which are bases for people's activities, with a view toward the realization of a harmonized society where the environment, wellbeing and economic growth coexist in harmony as envisioned in the Inspire 2027, Hitachi Group's new management plan. To address social issues, including the decline in the working population and carbon neutrality, the new exhibition will use AI, digital twin, and augmented reality (AR) technologies to propose the latest solutions addressed by One Hitachi, including HMAX for Buildings: BuilMirai, a suite of next-generation solutions that combine domain knowledge and advanced AI.In the future, Hitachi and Hitachi Building Systems will advance collaborative creation with developers, design offices, construction companies, owners of buildings, building management companies and other customers, as well as with partners at the Hitachi Building Solutions Lab.Outline of the new exhibition1. Building management using physical AI realized using digital twin technologiesTo address the labor shortage in building management operations, the new exhibition will propose a future vision for building management in a demonstration that combines AI and digital twin solutions, based on the latest technologies being developed by Hitachi's Research & Development Group. Visitors will be able to experience a digital twin solution for the operation of a guide robot in a physical space after they view optimal solutions proposed by an AI agent based on the results of people flow analyses and provide instructions to the robot in a virtual space.2. Air conditioning and demand control solution to accelerate GX and ZEB*1The exhibition will propose solutions for decarbonizing and reducing energy expenses of buildings with a view toward the achievement of carbon neutrality in 2050. The Hitachi Building Solutions Lab will provide an experience-based exhibition that visualizes the exiida air conditioning IoT solution from Hitachi Global Life Solutions, Inc. (“Hitachi GLS”, part of Hitachi’s CI Sector) and controls an actual business-use air conditioning system using AR technologies.*1 GX: Green Transformation ZEB: Net Zero Energy Building3. Seeking seamless movement within buildings and wellbeingThe exhibition will propose experiences that facilitate seamless movement using integrated elevators and other building equipment with a view toward supporting people's diverse workstyles and increasing the safety and quality of life (QoL) of building users. It will enable visitors to experience the link between the connected features of Hitachi's standard elevator set to be released in April 2026 and mobile robots, connections with the Hybrid-PCS vehicle-to-everything (V2X) system*2 capable of supplying power to elevators and other building equipment by connecting to electric vehicles during a power outage, and the latest security system using an Apple Wallet authentication system*3 .*2 V2X: Vehicle to Everything (Technology enabling electric vehicles, residential houses, buildings and the power grid, etc. to supply power to each other by connecting vehicles to various devices and infrastructure.)*3 Contactless authentication system using smartphones. In this system, users' identification documents and driver's licenses are registered in the Apple Wallet application so that the user's identity and age can be verified in real time using Face ID, Touch ID or NFC.4. Strengthening comprehensive solution capabilities such as One Hitachi To address increasingly diverse and complicated social issues and mission-critical areas, the exhibition will showcase examples of the Hitachi Group's solutions in its broad range of business sectors centered on HMAX for Buildings and products in the CI Sector. They will include AI safety solutions*4 to facilitate increased work efficiency and improved safety for frontline engineers, Hitachi Industrial Equipment Systems Co., Ltd.'s generative AI agent for the provision of dialogue-based information on the operation and maintenance of industrial equipment, and Hitachi GLS' connected home appliances. This will strengthen Hitachi's comprehensive ability to propose solutions as One Hitachi.*4 News released on November 14, 2025: Hitachi Commences the On-Site Application of an AI-Based Safety Solution for Engineers in the Field — Dangerous Location Notification https://www.hitachi.com/New/cnews/month/2025/11/251114a.htmlOutline of the Hitachi Building Solutions Lab Address : 4-16-29 Nakagawa, Adachi-ku, TokyoDate of opening : April 2, 2023Closed on : Saturdays, Sundays, national holidays and Hitachi's non-business daysOperating hours : 10:00 a.m. to 5:00 p.m.Tour style : Fully attended tours by reservation only (In principle, tours are open only to developers, design offices, constructors, owners of buildings, management associations and other customers and partners.)Hitachi’s CI Sector focuses on “Integrated Industry Automation,” which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for industry field that combine data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, Hitachi Building Systems aims to drive innovation for frontline engineers and contribute to improving people's wellbeing through the delivery of HMAX for Buildings: BuilMirai that embodies Lumada 3.0.An exhibit introducing AI safety solution for frontline engineers and Hitachi’s smart building services through digitalsignage, highlighting on-site transformation powered by AI.Trademark Notice: All trademarks and product names are the property of their respective owners.Hitachi Building Systems Websitehttps://www.hbs.co.jp/Hitachi Global Websitehttps://www.hitachi.com/businesses/elevator/About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制

东京, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.(总公司:东京都中央区、执行总裁:田中 浩一朗)宣布在以体外诊断试剂为代表的各种检测试剂盒的受托制造业务中,确立了可一站式应对整个工序的全面解决方案体制。TANAKA此前主要开展从检测试剂盒的开发制造到提取液的批量制造的相关业务,此次完善了提取液分装及包装的生产线,实现了在公司内部从开发到最终成品制造完成闭环的一条龙体制。由此不仅降低了外包和运输的相关成本,还缩短了生产周期,使我们能够以更短的期间提供更高质量的产品。此外,我们计划于2026年3月前追加引进最新型的自动装配生产线和提取液分装装置,以进一步扩大产能及缩短备货周期。TANAKA的全面解决方案体制通过强化一条龙生产体制实现灵活应对通过此次确立的全面解决方案体制,我们实现了从检测试剂盒开发制造,到提取液的批量制造及分装、包装等各工序的一站式受托服务。由此不仅能够对客户从开发阶段到量产的过程持续提供支持,还能应对仅药液分装等单一工序的委托。通过生产流程的公司内部闭环,来实现进一步强化稳定供应与质量管理。在广泛的疾病领域中的检测试剂盒的开发实绩与拓展示例我们提供针对流感、新型冠状病毒等呼吸道传染病,以及登革热病毒、寨卡病毒等范围广泛的传染病的体外诊断试剂。这些检测试剂盒可应对唾液、血液、尿液等多种检体,为在医疗领域实现快速精准的诊断提供支持。呼吸道传染病蚊媒传染病妇产科・流感病毒・腺病毒・RS病毒・人偏肺病毒・新型冠状病毒・A群β溶血链球菌(溶连菌)・登革热病毒・寨卡病毒・基孔肯雅热病毒・怀孕检测试剂TANAKA可检测疾病领域拓展示例技术基础与今后的展望TANAKA自2006年左右开始研发体外诊断试剂,不断培养以金(Au)胶体粒子为核心的相关技术。已拥有蛋白质固定化技术、非特异性吸附抑制技术、抗原抗体反应增强技术等,通过免疫层析法实现试剂更高性能化的多种技术。此外,还依托ISO 13485认证,有效利用这些技术,承接更高质量检测试剂盒的委托制造。今后仍将充分利用这一全面解决方案体制,在与合作伙伴企业协作的同时,致力于新型诊断试剂的开发工作,并为解决社会课题和推动医疗领域的发展做出贡献。关于TANAKATANAKA自1885 年(明治18年)创业以来,营业范围以贵金属为中心,并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售,以及提供作为宝石饰品及资产的贵金属商品。并且,作为贵金属相关的专家集团,日本国内外的各集团公司进行制造、销售以及技术一体化,携手合作提供产品及服务。2024年度(截至2024年12月)集团总营业额为8,469亿日元,拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20260205_CH.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

年度最超现实的时间旅行电影,是一位深受喜爱的导演的回归之作

摄影:Benjamin Loeb(SeaPRwire) -   一位女子若有所思地凝视镜头,她乌黑的发丝在风中翻飞,遮住了脸庞。这个画面在Kogonada最新的梦幻科幻剧情片《Zi》中反复出现——该片刚在圣丹斯电影节完成首映。这是一段若隐若现的记忆?是对未来的预见?亦或两者皆是?《Zi》的奇异科幻剧情便围绕这一问题展开:一名女子开始频繁看到未来的自己。但影片如耳语般轻盈的叙事和即兴的结构,让Kogonada得以深入挖掘他一贯擅长的梦幻、存在主义电影维度,使得《Zi》成为导演继去年那部笨拙宏大的作品后,令人欣喜的“回归之作”。尽管《Zi》轻得近乎飘渺,却无疑令人过目不忘。Michelle Mao在《Zi》中呈现出空灵气质。| 摄影:Benjamin Loeb故事始于同名女主角小姿(Michelle Mao饰)前往香港祭拜父母,她因未能为父母做更多而哀伤。随后,她恍恍惚惚地穿过繁华的街道,最终在一处偏僻的楼梯前停下,崩溃痛哭。一位自称艾儿(Haley Lu Richardson饰)的陌生女子关切询问她是否安好,但小姿只是困惑地凝视对方——这份困惑很快转为震惊。她曾见过艾儿,当时艾儿身旁站着一个与自己极为相似的女子。此刻起,小姿开始怀疑自己看到了未来的自己。但她并不相信自己拥有超自然能力,反而将这些幻觉归咎于此前在香港神经学中心检查时可能发现的脑部肿瘤。愈发担忧的艾儿提出带她去见自己的神经科医生朋友敏(Jin Ha饰),以进一步了解病情,三人由此开启了一段穿越香港街头的奇异漫游,他们的过去与现在交织碰撞。《Zi》以从容舒缓的节奏展开一场通宵漫游,与其说是电影,更像一首情绪诗。它通过小姿、艾儿与敏之间笨拙却直抵人心的互动,以及前文提及的小姿特写等模糊画面推进。这些幻象——包括一位老妇安慰年长版小姿的重复画面——如同等待小姿拼凑的拼图,有些在当晚便应验,有些则是对未来的遥远预见。除了敏诊断小姿患有的“时间相对论”病症外,这些幻象并未指向更宏大的剧情或更高的 stakes(关键冲突)。它们是影片“偷来的瞬间与流逝的时间”构成的梦幻底色的一部分——这种对人性的碎片化刻画,正是Kogonada在其精妙科幻杰作《之后的杨》中便擅长的。而在《Zi》里,这种刻画更显模糊,且是导演刻意为之。影片单薄的剧情是特色而非缺陷,源于Kogonada的一次实验。这部电影的诞生,始于Kogonada邀请六位密友(包括Mao、Richardson、Ha,以及他长期合作的摄影师Benjamin Loeb、制片人Chung An和Christopher Radcliff)自费飞往香港,带着模糊的电影大纲和微薄的预算。他们边拍摄边打磨创意,三周后完成了《Zi》。在经历了《Big Bold Beautiful Journey》视觉铺张带来的不适后,Kogonada在轻盈的《Zi》中重归舒适区——某种程度上,它像是《Journey》的“负片”。《Journey》宏大之处,它细腻;《Journey》戏剧化之处,它静谧;《Journey》野心勃勃之处,它谦逊。但正如《Journey》中Kogonada对电影灵感的融合(大量借鉴宫崎骏作品),《Zi》也汲取了其他导演的养分——王家卫的视觉诗性,或理查德·林克莱特“漫游电影”的温情。Kogonada对香港街头节奏与人群的关注(Loeb以近乎纪录片的方式用镜头温柔捕捉),最易让人联想到王家卫。而《Zi》对神秘画面的闪回、对单一画面的反复呈现(深深刻在主角与观众脑海中),则最直白地让人想起克里斯·马克1962年的短片《堤》——该片后来启发了特瑞·吉列姆的《十二猴子》。在《哥伦布》与《之后的杨》中均有出演后,Haley Lu Richardson已证明自己是Kogonada最默契的银幕合作者。| 摄影:Benjamin Loeb《Zi》如电影致敬集般的气质未必是缺点,但确实让它与《Journey》更显一脉相承:两部作品都展现了Kogonada试图将电影灵感转化为个人风格的努力。所幸《Zi》表明,他离这个目标更近了一步。正是因为《Zi》是一部如此私密的人物片——高度依赖小姿、艾儿与敏之间的亲密瞬间——它才得以在轻盈中留下不可磨灭的印记。Mao演绎出了角色脆弱迷茫的魅力;Richardson则再次证明自己是Kogonada最可靠的银幕搭档,即便导演给她戴上最廉价的假发,她仍能用带着伤痕的灵动点亮银幕。Ha饰演的敏则成为小姿与艾儿坚实温暖的锚点:他默默爱慕艾儿,同时尽力提醒小姿注意病情。“对你来说,过去永远挥之不去,”他对小姿说。这既是她的写照,也是这部电影的注脚——它已像一张快照,记录着一个快速消逝的时空,用一种同样正在消失的方式拍摄。这是低保真科幻的最佳形态,也是最令人难忘的形态。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。《Zi》于2026年1月24日在圣丹斯电影节首映,目前正寻求发行。